Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis

Shin, Beomsu; Koh, Won‐Jung; Jeong, Byeong‐Ho; Yoo, Hongseok; Park, Hye Yun; Suh, Gee Young; Kwon, O Jung; Jeon, Kyeongman

doi:10.1016/j.jinf.2014.01.005

Cited by 74 publications

(61 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study, the detection of galactomannan antigen in BAL specimens was found to be more sensitive (85.7 %) and more specific (76.3 %) than the detection in the serum of CPA patients [33]. Furthermore, a recent study in 334 patients with CPA concluded that the serum galactomannan test cannot be used for the serological diagnosis of CPA [34]. In our case series, the serum assay for BG was positive for the majority of patients (76.1 %).…”

Section: Discussionmentioning

confidence: 99%

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In another study the BAL GM-antigen detection test had a sensitivity and specificity of 85.7% and 76.3%, respectively, with a cut-off level of >0.5 [28]. In a recent study, the sensitivity of serum GM was only 23% [39]. Thus BAL (SoR B, QoE II) and not serum GM (SoR C and QoE III) should be used in diagnosis of CPA.…”

Section: Contribution Of Galactomannan Antigen To the Diagnosis Of Cpamentioning

confidence: 94%

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Denning¹,

Cadranel²,

et al. 2015

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) is an uncommon and problematic pulmonary disease, complicating many other respiratory disorders, thought to affect ∼240 000 people in Europe. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), which untreated may progress to chronic fibrosing pulmonary aspergillosis. Less common manifestations include: Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (<3 months) usually found in moderately immunocompromised patients, which should be managed as invasive aspergillosis. Few clinical guidelines have been previously proposed for either diagnosis or management of CPA. A group of experts convened to develop clinical, radiological and microbiological guidelines. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp. and exclusion of alternative diagnoses, all present for at least 3 months. Aspergillus antibody (precipitins) is elevated in over 90% of patients. Surgical excision of simple aspergilloma is recommended, if technically possible, and preferably via video-assisted thoracic surgery technique. Long-term oral antifungal therapy is recommended for CCPA to improve overall health status and respiratory symptoms, arrest haemoptysis and prevent progression. Careful monitoring of azole serum concentrations, drug interactions and possible toxicities is recommended. Haemoptysis may be controlled with tranexamic acid and bronchial artery embolisation, rarely surgical resection, and may be a sign of therapeutic failure and/or antifungal resistance. Patients with single Aspergillus nodules only need antifungal therapy if not fully resected, but if multiple they may benefit from antifungal treatment, and require careful follow-up. @ERSpublications ERS and ESCMID guideline for the management of chronic pulmonary aspergillosis released

show abstract

“…However, these subtypes usually overlap and are difficult to differentiate clinically. Thus, many investigators refer to these subtypes merely as CPA (3)(4)(5)(6)(7)(8).CPA is a slowly progressive pulmonary syndrome caused by Aspergillus spp. It is saprophytic in persons with underlying pulmonary conditions such as old tuberculosis, pulmonary emphysema, and previous thoracic surgery (9).…”

mentioning

confidence: 99%

Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β- d -Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis

et al. 2017

View full text Add to dashboard Cite

We evaluated the usefulness of an Aspergillus galactomannan (GM) test, a ␤-D-glucan (␤DG) test, and two different Aspergillus PCR assays of bronchoalveolar lavage fluid (BALF) samples for the diagnosis of chronic pulmonary aspergillosis (CPA). BALF samples from 30 patients with and 120 patients without CPA were collected. We calculated the sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio for each test individually and in combination with other tests. The optical density index values, as determined by receiver operating characteristic analysis, for the diagnosis of CPA were 0.5 and 100 for GM and ␤DG testing of BALF, respectively. The sensitivity and specificity of the GM test, ␤DG test, and PCR assays 1 and 2 were 77.8% and 90.0%, 77.8% and 72.5%, 86.7% and 84.2%, and 66.7% and 94.2%, respectively. A comparison of the PCR assays showed that PCR assay 1 had a better sensitivity, a better negative predictive value, and a better negative likelihood ratio and PCR assay 2 had a better specificity, a better positive predictive value, and a better positive likelihood ratio. The combination of the GM and ␤DG tests had the highest diagnostic odds ratio. The combination of the GM and ␤DG tests on BALF was more useful than any single test for diagnosing CPA.KEYWORDS chronic pulmonary aspergillosis, Aspergillus galactomannan test, ␤-D-glucan test, Aspergillus PCR assays T he Aspergillus spp. are ubiquitous saprophytic fungi and are the pathogens most commonly responsible for pulmonary fungal disease worldwide. They cause a variety of diseases, including invasive and chronic aspergillosis and allergic disease (1). Chronic pulmonary aspergillosis (CPA) is classified into three major subtypes: chronic necrotizing pulmonary aspergillosis, chronic cavitary pulmonary aspergillosis, and chronic fibrosing pulmonary aspergillosis (2). However, these subtypes usually overlap and are difficult to differentiate clinically. Thus, many investigators refer to these subtypes merely as CPA (3)(4)(5)(6)(7)(8).CPA is a slowly progressive pulmonary syndrome caused by Aspergillus spp. It is saprophytic in persons with underlying pulmonary conditions such as old tuberculosis, pulmonary emphysema, and previous thoracic surgery (9). CPA is diagnosed by evaluating clinical symptoms, radiological findings, and the results from serum Aspergillus antibody testing and Aspergillus sp. culture. These diagnostic criteria are based on a

show abstract

Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis

Cited by 74 publications

References 15 publications

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β- d -Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis

Contact Info

Product

Resources

About